SCHEMBL2477291

SCHEMBL2477291

C=Cc1cccn(-c2c(C)cc([N+](=O)[O-])cc2C)c1=O

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.39
POLB P06746 3/20 0.39
TDP1 Q9NUW8 3/20 0.37
TSHR P16473 3/20 0.37
KMT2A Q03164 5/20 0.36
MEN1 O00255 4/20 0.36
MAPT P10636 3/20 0.36
L3MBTL1 Q9Y468 3/20 0.36
RECQL P46063 1/20 0.36
MCL1 Q07820 1/20 0.36
CYP3A4 P08684 1/20 0.36
KDM4E B2RXH2 1/20 0.35
MAPK1 P28482 2/20 0.35
NR4A1 P22736 1/20 0.35
GPR35 Q9HC97 1/20 0.34
GAA P10253 1/20 0.33
ACHE P22303 1/20 0.33
HPGD P15428 1/20 0.33
MITF O75030 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2473566 0.85 ALDH1A1 (0.42) ALDH1A1POLBTDP1TSHRKMT2A
SCHEMBL3644238 0.80 ALDH1A1 (0.43) ALDH1A1POLBTDP1TSHRKMT2A
SCHEMBL2473570 0.80 ALDH1A1 (0.41) ALDH1A1POLBTDP1TSHRKMT2A
SCHEMBL3424022 0.77 ALDH1A1 (0.43) ALDH1A1POLBTDP1TSHRKMT2A
SCHEMBL2471712 0.75 RAB9A (0.38) ALDH1A1POLBTDP1TSHRKMT2A
SCHEMBL2473594 0.74 HTT (0.44) ALDH1A1POLBTDP1KMT2AMEN1
SCHEMBL2474270 0.74 NR1H2 (0.36) ALDH1A1POLBTSHRKMT2AMEN1
SCHEMBL2474273 0.74 NR1H2 (0.36) ALDH1A1POLBTSHRKMT2AMEN1
SCHEMBL15929085 0.73 MAPT (0.36) ALDH1A1POLBTDP1TSHRKMT2A
SCHEMBL27909201 0.73 RECQL (0.45) ALDH1A1POLBTDP1TSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2563762-B1 METHOD FOR PRODUCING SUBSTITUTED PYRIDIN-2-ONE BAYER IP GMBH (DE) 2015-07-22 EP disclosed
CN-102906071-B Method for producing substituted pyridin-2-one BAYER IP GMBH 2015-03-18 CN disclosed
US-8846934-B2 Substituted oxazolidinones and their use BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-09-30 US disclosed
US-8846934-B2 Substituted oxazolidinones and their use BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-09-30 US disclosed
US-8846934-B2 Substituted oxazolidinones and their use BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-09-30 US disclosed
US-20140057951-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-02-27 US disclosed
US-20140057951-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-02-27 US disclosed
US-20140057951-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-02-27 US disclosed
US-8487111-B2 Substituted oxazolidinones and their use BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-07-16 US disclosed
US-8487111-B2 Substituted oxazolidinones and their use BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-07-16 US disclosed
US-8383822-B2 Substituted oxazolidinones and their use BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-02-26 US disclosed
US-8383822-B2 Substituted oxazolidinones and their use BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-02-26 US disclosed
EP-2170877-B1 SUBSTITUTED (OXAZOLIDINON-5-YL-METHYL) -2-THIOPHENE-CARBOXAMIDES AND USE THEREOF IN THE FIELD OF BLOOD COAGULATION BAYER IP GMBH (DE) 2012-11-21 EP disclosed
EP-2173744-B1 SUBSTITUTED (OXAZOLIDINON-5-YL-METHYL) -2-THIOPHENE-CARBOXAMIDES AND USE THEREOF IN THE FIELD OF BLOOD COAGULATION Bayer Pharma AG (DE) 2011-10-05 EP disclosed
US-20100261759-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-10-14 US disclosed
US-20100261759-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-10-14 US disclosed
US-20100261759-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-10-14 US disclosed
US-20100184740-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-07-22 US disclosed
US-20100184740-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-07-22 US disclosed
US-20100184740-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-07-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140057951-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE XDH, MPL, OXA1L ALDH1A1 523/4885POLB 810/4885TDP1 2020/4885
US-20100184740-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE XDH, MPL, OXA1L ALDH1A1 523/4885POLB 810/4885TDP1 2020/4885
US-20100261759-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE XDH, MPL, OXA1L ALDH1A1 523/4885POLB 810/4885TDP1 2020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.